Successful treatment of anti-GAD antibody-associated autoimmune cerebellar ataxia with combined immunotherapies

被引：0

作者：

Omote, Yoshio ^{[1
]}

Matsuoka, Chika ^{[1
]}

Sasaki, Ryo ^{[1
]}

Hishikawa, Nozomi ^{[1
]}

Kawahara, Yuko ^{[1
]}

Nomura, Emi ^{[1
]}

Matsumoto, Namiko ^{[1
]}

Taira, Yuki ^{[1
]}

Takemoto, Mami ^{[1
]}

Morihara, Ryuta ^{[1
]}

Yamashita, Toru ^{[1
]}

Abe, Koji ^{[1
]}

机构：

[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol, 2-5-1 Shikata Cho, Okayama 7008558, Japan

来源：

NEUROLOGY AND CLINICAL NEUROSCIENCE | 2021年 / 9卷 / 06期

关键词：

anti-glutamic acid decarboxylase antibody; cerebellar ataxia; immunotherapy; GLUTAMIC-ACID DECARBOXYLASE;

D O I：

10.1111/ncn3.12541

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Anti-glutamic acid decarboxylase (GAD) antibody (Ab)-associated autoimmune cerebellar ataxia (CA) is a rare neurological disorder, and a standardized therapy has not been established. Here, we report on a 58 year-old man with type 1 diabetes mellitus, who developed progressive CA with high levels of serum and cerebrospinal fluid (CSF) anti-GAD-Ab. He was initially treated with intravenous high-dose methylprednisolone and intravenous immunoglobulin (IVIg), but his CA was gradually worsened. Additional combined immunotherapies with plasma exchange, intravenous cyclophosphamide, and rituximab finally stabilized the progressive CA and suppressed the CSF anti-GAD-Ab index. Our case suggests the effectiveness of combined immunotherapies against progressive CA and the usefulness of the CSF anti-GAD-Ab index as a therapeutic indicator.

引用

页码：474 / 477

页数：4

共 6 条

[1] Stiff person syndrome -: Quantification, specificity, and intrathecal synthesis of GAD65 antibodies [J].